Supplementary Fig. 2 from Anti-tumor efficacy of the novel KIT inhibitor IDRX-42 (formerly M4205) in patient- and cell line-derived xenograft models of gastrointestinal stromal tumor (GIST) | Synapse
September 16, 2024
Supplementary Fig. 2 from Anti-tumor efficacy of the novel KIT inhibitor IDRX-42 (formerly M4205) in patient- and cell line-derived xenograft models of gastrointestinal stromal tumor (GIST)
Key Points
Key points are not available for this paper at this time.
Abstract
Supplementary Fig. 2. Individual absolute tumor volumes per experiment and per treatment group on the first and last day of experiment.